Your browser doesn't support javascript.
loading
Capicua suppresses colorectal cancer progression via repression of ETV4 expression.
Lee, Jeon-Soo; Kim, Eunjeong; Lee, Jongeun; Kim, Donghyo; Kim, Hyeongjoo; Kim, Chang-Jin; Kim, Sanguk; Jeong, Dongjun; Lee, Yoontae.
Afiliação
  • Lee JS; 1Department of Life Sciences, Pohang University of Science and Technology, Pohang, Gyeongbuk Republic of Korea.
  • Kim E; 1Department of Life Sciences, Pohang University of Science and Technology, Pohang, Gyeongbuk Republic of Korea.
  • Lee J; 1Department of Life Sciences, Pohang University of Science and Technology, Pohang, Gyeongbuk Republic of Korea.
  • Kim D; 1Department of Life Sciences, Pohang University of Science and Technology, Pohang, Gyeongbuk Republic of Korea.
  • Kim H; 3Soonchunhyang Medical Science Research Institute, Soonchunhyang University, Cheonan, Chungnam Republic of Korea.
  • Kim CJ; 4Department of Pathology, College of Medicine, Soonchunhyang University, Room 601, 31 Soonchunhyang 6gil, Dongnam-gu, Cheonan, Chungnam 31151 Republic of Korea.
  • Kim S; 1Department of Life Sciences, Pohang University of Science and Technology, Pohang, Gyeongbuk Republic of Korea.
  • Jeong D; 2Division of Integrative Bioscience and Biotechnology, Pohang University of Science and Technology, Pohang, Gyeongbuk Republic of Korea.
  • Lee Y; 3Soonchunhyang Medical Science Research Institute, Soonchunhyang University, Cheonan, Chungnam Republic of Korea.
Cancer Cell Int ; 20: 42, 2020.
Article em En | MEDLINE | ID: mdl-32042269
ABSTRACT

BACKGROUND:

Although major driver gene mutations have been identified, the complex molecular heterogeneity of colorectal cancer (CRC) remains unclear. Capicua (CIC) functions as a tumor suppressor in various types of cancers; however, its role in CRC progression has not been examined.

METHODS:

Databases for gene expression profile in CRC patient samples were used to evaluate the association of the levels of CIC and Polyoma enhancer activator 3 (PEA3) group genes (ETS translocation variant 1 (ETV1), ETV4, and ETV5), the best-characterized CIC targets in terms of CIC functions, with clinicopathological features of CRC. CIC and ETV4 protein levels were also examined in CRC patient tissue samples. Gain- and loss-of function experiments in cell lines and mouse xenograft models were performed to investigate regulatory functions of CIC and ETV4 in CRC cell growth and invasion. qRT-PCR and western blot analyses were performed to verify the CIC regulation of ETV4 expression in CRC cells. Rescue experiments were conducted using siRNA against ETV4 and CIC-deficient CRC cell lines.

RESULTS:

CIC expression was decreased in the tissue samples of CRC patients. Cell invasion, migration, and proliferation were enhanced in CIC-deficient CRC cells and suppressed in CIC-overexpressing cells. Among PEA3 group genes, ETV4 levels were most dramatically upregulated and inversely correlated with the CIC levels in CRC patient samples. Furthermore, derepression of ETV4 was more prominent in CIC-deficient CRC cells, when compared with that observed for ETV1 and ETV5. The enhanced cell proliferative and invasive capabilities in CIC-deficient CRC cells were completely recovered by knockdown of ETV4.

CONCLUSION:

Collectively, the CIC-ETV4 axis is not only a key module that controls CRC progression but also a novel therapeutic and/or diagnostic target for CRC.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancer Cell Int Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancer Cell Int Ano de publicação: 2020 Tipo de documento: Article